WE AIM TO SPEED UP PATIENTS' ACCESS TO INNOVATIVE THERAPIES BY COLLABORATING WITH CUTTING-EDGE PHARMACEUTICAL COMPANIES.

FACTS

14 CLINICS In 8 countries in Europe,
North America and Africa
MORE...
15 TO 60 DAYS Fast start-up/regulatory
timelines
MORE...
5 TO 30-FOLD Patient enrollment
vs competition
MORE...
9 TO 24 MONTHS PROOF-OF-CONCEPT MORE...

DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

Timely access to new therapies is critical for patients, providing them with better treatment options and potentially life-saving solutions. The pharmaceutical industry faces pressure to develop new therapies rapidly and efficiently while maintaining data safety and quality.

ARENSIA’s playing field

The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.

Industry challenge

The demand for advanced Phase I/II PROOF OF CONCEPT clinical trials requires specialized research personnel and facilities. However, traditional clinical trial sites often lack these resources, prompting pharmaceutical companies to involve multiple sites for trials, resulting in high costs and delays for protocols with low patient numbers (12-200).

ARENSIA solution

At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.

All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.

Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a significant budget reduction for Phase IB/IIA PROOF-OF-CONCEPT trials.

Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs.

WATCH THIS VIDEO Find out more about us in 2 minutes

WHAT OUR SPONSORS SAID

In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.

Leading Global Pharmaceutical Company, US based

We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.

Mid-Size Biotech Company, US based

We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.

Leading Global CRO, US based

NEWS

ARENSIA HAS SIGNIFICANTLY EXPEDITED A PHASE IB TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS ARENSIA HAS SIGNIFICANTLY EXPEDITED A PHASE IB TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS 24.06.2024

In Ukraine alone, rare diseases like IPF affect 10-15 people out of 100.000 population, typically diagnosed in individuals over 40. Without treatment,...

READ MORE
ARENSIA ENROLLS FIRST PATIENT WORLDWIDE IN COMPLEX MULTIPLE SCLEROSIS STUDY! ARENSIA ENROLLS FIRST PATIENT WORLDWIDE IN COMPLEX MULTIPLE SCLEROSIS STUDY! 19.03.2024

We love being in the lead! ARENSIA has once again achieved a significant milestone by enrolling the first patient globally, this time in a complex mul...

READ MORE
HAPPY INTERNATIONAL WOMEN`S DAY HAPPY INTERNATIONAL WOMEN`S DAY 08.03.2024

Today, we honor the remarkable achievements, strength, and resilience of women worldwide. Let's stand united, empower each other, and continue bre...

READ MORE
MOLDOVA IMPLEMENTS 10-DAY REVIEW TIMELINES FOR CLINICAL TRIALS! MOLDOVA IMPLEMENTS 10-DAY REVIEW TIMELINES FOR CLINICAL TRIALS! 04.03.2024

The Health Authority (HA) of Moldova has introduced a 10-day fast-track review timeline for all phases (I-III) of clinical trials, with the regular re...

READ MORE
FIRST CALL INNOVATIONXCHANGE BY ARENSIA IN ZURICH FIRST CALL INNOVATIONXCHANGE BY ARENSIA IN ZURICH 15.01.2024

Following a resonant success from San Francisco, we are thrilled to announce the next edition in the summit series: "RACE FOR PROOF OF CONCEPT...

READ MORE
CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNTIES CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNTIES 10.01.2024

🔊 FIRST CALL! LIVE WEBINAR 📈 CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNITIES 📅 Monday, February 5, 2024 ⏰ 5:00 PM CET / 11:00 A...

READ MORE
ARENSIA WEBSITE AVAILABLE IN MANDARIN ARENSIA WEBSITE AVAILABLE IN MANDARIN 04.01.2024

The New Year starts with great news! The ARENSIA website is now available in Mandarin! This is a result of the growing interest of companies from the ...

READ MORE
CONTACT US